Skip to main content

AIRSUPRA

SABAICS MDI

Albuterol / Budesonide · AstraZeneca

Clinical Reference · Data reviewed June 2026

Active Medication & Mechanism

  • Albuterol sulfate SABA
    90 mcg albuterol per actuation

    Short-acting beta2-adrenergic agonist. Relaxes bronchial smooth muscle by activating beta2-receptors, increasing cAMP, and producing rapid bronchodilation within minutes.

  • Budesonide ICS
    80 mcg per actuation

    Corticosteroid with anti-inflammatory properties. Reduces airway inflammation and edema to help prevent worsening of symptoms during acute episodes.

FDA-Approved Dosing — Strength × Indication

90/80 mcg 2 inhalations as needed for bronchoconstriction symptoms → Maximum 12 inhalations (1080/960 mcg) per 24 hours
Asthma FDA Approved
For the as-needed treatment or prevention of bronchoconstriction and to reduce the risk of exacerbations in adults with asthma. Not for scheduled maintenance use.

All regimens shown apply to adults (≥18 years) unless otherwise noted · verify against current labelling

Rescue inhaler. Indicated for as-needed treatment or prevention of bronchoconstriction and to reduce exacerbation risk in asthma. Not for scheduled maintenance therapy.

For educational reference by healthcare professionals. Not medical advice and not for use in clinical decision-making. This workspace is not a substitute for clinical judgement, prescribing information, or product monographs — always verify doses and indications against the most current labelling. If you are a patient, do not use this site to make medication decisions — speak with your clinician.

Device images are original illustrations for identification aid only — actual devices and packaging may differ. This site is not affiliated with or endorsed by any pharmaceutical manufacturer. Clinical data last reviewed: June 2026.

Inhaler Database · © inhalerdatabase.com 2024–2026 — All rights reserved